Do organic substances act as a degradable binding matrix in calcium oxalate kidney stones?


Journal

BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571

Informations de publication

Date de publication:
26 Mar 2021
Historique:
received: 10 02 2021
accepted: 18 03 2021
entrez: 26 3 2021
pubmed: 27 3 2021
medline: 27 8 2021
Statut: epublish

Résumé

Calcium oxalate (CaOx) stones are considered to be highly resistant to chemolysis. While significant organic matter has been identified within these stones, which is presumed to bind (inorganic) CaOx particles and aggregates, most chemolysis efforts have focused on methods to attack the CaOx components of a stone. We examine the feasibility of inducing chemolysis of CaOx kidney stones, within hours, by specifically attacking the organic matrix present in these stones. In contrast to previous studies, we focused on the possible "brick and mortar" stone configuration. We systematically tested, via in vitro experiments, the ability of an extensive range of 26 potential chemolysis agents to induce relatively fast disintegration (and/or dissolution) of a large set of natural CaOx stone fragments, extracted during endourological procedures, without regard to immediate clinical application. Each stone fragment was monitored for reduction in weight and other changes over 72 h. We find that agents known to attack organic material have little, if any, effect on stone chemolysis. Similarly, protein and enzymatic agents, and oral additive medical treatments, have little immediate effect. These findings suggest that the organic and inorganic constituents present in CaOx stones are not structured as "brick and mortar" configurations in terms of inorganic and organic components.

Sections du résumé

BACKGROUND BACKGROUND
Calcium oxalate (CaOx) stones are considered to be highly resistant to chemolysis. While significant organic matter has been identified within these stones, which is presumed to bind (inorganic) CaOx particles and aggregates, most chemolysis efforts have focused on methods to attack the CaOx components of a stone. We examine the feasibility of inducing chemolysis of CaOx kidney stones, within hours, by specifically attacking the organic matrix present in these stones.
METHODS METHODS
In contrast to previous studies, we focused on the possible "brick and mortar" stone configuration. We systematically tested, via in vitro experiments, the ability of an extensive range of 26 potential chemolysis agents to induce relatively fast disintegration (and/or dissolution) of a large set of natural CaOx stone fragments, extracted during endourological procedures, without regard to immediate clinical application. Each stone fragment was monitored for reduction in weight and other changes over 72 h.
RESULTS RESULTS
We find that agents known to attack organic material have little, if any, effect on stone chemolysis. Similarly, protein and enzymatic agents, and oral additive medical treatments, have little immediate effect.
CONCLUSIONS CONCLUSIONS
These findings suggest that the organic and inorganic constituents present in CaOx stones are not structured as "brick and mortar" configurations in terms of inorganic and organic components.

Identifiants

pubmed: 33765979
doi: 10.1186/s12894-021-00818-3
pii: 10.1186/s12894-021-00818-3
pmc: PMC7995742
doi:

Substances chimiques

Calcium Oxalate 2612HC57YE

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

46

Références

Urol Res. 2001 Apr;29(2):83-8
pubmed: 11396733
Clin Chim Acta. 2002 Aug;322(1-2):29-36
pubmed: 12104078
BMC Urol. 2005 May 22;5:9
pubmed: 15907215
Urolithiasis. 2013 Aug;41(4):323-6
pubmed: 23743991
Sci Rep. 2018 Sep 13;8(1):13731
pubmed: 30213974
Pediatr Nephrol. 2010 Jan;25(1):49-59
pubmed: 21476230
Free Radic Biol Med. 1993 Dec;15(6):645-51
pubmed: 8138191
Am J Physiol Renal Physiol. 2008 Feb;294(2):F355-61
pubmed: 18077596
Nat Rev Dis Primers. 2016 Feb 25;2:16008
pubmed: 27188687
Urolithiasis. 2017 Feb;45(1):11-18
pubmed: 27900406
Sci Rep. 2017 May 3;7(1):1415
pubmed: 28469190
Calcif Tissue Int. 1988 Nov;43(5):319-27
pubmed: 3145798
Rev Urol. 2009 Summer;11(3):134-44
pubmed: 19918339
Eur J Pharmacol. 2012 Aug 15;689(1-3):219-25
pubmed: 22713548
Proteome Sci. 2016 Feb 27;14:4
pubmed: 26924944
World J Urol. 2015 Feb;33(2):157-69
pubmed: 25465911
Urology. 2011 Sep;78(3):721.e13-721.e17
pubmed: 21741690
BMJ. 2016 Mar 14;352:i52
pubmed: 26977089
Am J Med. 1968 Nov;45(5):673-83
pubmed: 5687257
Urol Res. 2012 Jun;40(3):205-9
pubmed: 22089056
J Endourol. 2012 Feb;26(2):110-8
pubmed: 21999455
Kidney Int. 1996 Mar;49(3):880-8
pubmed: 8648933
Int Braz J Urol. 2013 Jan-Feb;39(1):103-7
pubmed: 23489502
Urol Int. 2014;92(3):349-55
pubmed: 24246673
Urolithiasis. 2019 Aug;47(4):311-320
pubmed: 30915494
J Urol. 1956 Sep;76(3):213-27
pubmed: 13368269

Auteurs

Adi Adelman (A)

Department of Urology, Kaplan Medical Center, 7661041, Rehovot, Israel.

Yaniv Shilo (Y)

Department of Urology, Kaplan Medical Center, 7661041, Rehovot, Israel.

Jonathan Modai (J)

Department of Urology, Kaplan Medical Center, 7661041, Rehovot, Israel.

Dan Leibovici (D)

Department of Urology, Kaplan Medical Center, 7661041, Rehovot, Israel.

Ishai Dror (I)

Department of Earth and Planetary Sciences, Weizmann Institute of Science, 7610001, Rehovot, Israel.

Brian Berkowitz (B)

Department of Earth and Planetary Sciences, Weizmann Institute of Science, 7610001, Rehovot, Israel. brian.berkowitz@weizmann.ac.il.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH